Revenue Performance - Total revenue decreased by $19.7 million, or 47%, for Q3 2023 compared to Q3 2022, primarily due to the timing of revenue recognition for guaranteed fixed minimum royalties under the NEB agreement[193] - Assay services revenue increased by $0.3 million (2%) in Q3 2023 compared to Q3 2022, driven by a $3.5 million increase in average selling price, offset by a $3.2 million decrease in sample volume[194] - Product revenue increased by $2.4 million in Q3 2023 compared to Q3 2022, primarily due to higher volume of kit and equipment sales[195] - Other revenue decreased by $22.3 million (100%) in Q3 2023 compared to Q3 2022, due to the timing of revenue recognition for guaranteed fixed minimum royalties under the NEB agreement[196] - Total revenue decreased by $15.9 million, or 20%, for the nine months ended September 30, 2023, primarily due to the timing of revenue recognition for guaranteed fixed minimum royalties[207] - Assay services revenue increased by $5.6 million, or 12%, for the nine months ended September 30, 2023, driven by an increase in sample volume[208] - Product revenue increased by $5.3 million for the nine months ended September 30, 2023, primarily due to higher sales volume of kits and equipment[208] Cost and Expense Analysis - Cost of assay services revenue decreased by $1.3 million (11%) in Q3 2023 compared to Q3 2022, primarily due to lower sample volume[198] - Cost of product revenue increased by $1.2 million in Q3 2023 compared to Q3 2022, driven by higher volume of kit and equipment sales[199] - Research and development expenses decreased by $9.0 million, or 46%, for the three months ended September 30, 2023, primarily due to reductions in consulting fees, supplies costs, and clinical studies costs[200] - Selling, general, and administrative expenses decreased by $25.6 million, or 52%, for the three months ended September 30, 2023, driven by reductions in stock-based compensation, wages, and marketing costs[201] - Transaction costs increased by $2.4 million, or 141%, for the three months ended September 30, 2023, related to the proposed merger with Standard BioTools[202] - Research and development expenses decreased by $15.5 million, or 31%, for the nine months ended September 30, 2023, due to reductions in consulting fees, supplies costs, and clinical studies costs[213] - Selling, general, and administrative expenses decreased by $28.4 million, or 24%, for the nine months ended September 30, 2023, driven by reductions in stock-based compensation and marketing costs[214] Financial Position and Liquidity - Interest income and other, net increased by $3.7 million, or 151%, for the three months ended September 30, 2023, due to higher interest rates[203] - Interest income and other, net increased by $13.3 million for the nine months ended September 30, 2023, due to higher interest rates[217] - Adjusted EBITDA for Q3 2023 was $(20.1) million, compared to $(30.2) million in Q3 2022, showing a year-over-year improvement[224] - Net loss for Q3 2023 was $(22.2) million, a decrease from $(32.9) million in Q3 2022[224] - Cash collected from customers in the first nine months of 2023 was $58.6 million, the primary source of liquidity[226] - Net cash used in operating activities for the first nine months of 2023 was $(90.6) million, compared to $(74.1) million in the same period of 2022[231] - Cash payments for employee compensation and other costs in the first nine months of 2023 were approximately $79.2 million[232] - The company had no outstanding debt as of September 30, 2023[227] - Future minimum lease commitments for administrative and laboratory facilities totaled $5.0 million as of September 30, 2023[230] - Net cash used in investing activities for the first nine months of 2023 was $(30.3) million, primarily due to increased purchases of marketable securities[235] - Cash provided by financing activities for the first nine months of 2023 was $0.4 million, a decrease from $4.9 million in the same period of 2022[236] - The company believes its existing cash and cash equivalents will support working capital and capital expenditure requirements for at least the next 12 months[225] Strategic Initiatives and Business Development - The company completed the acquisition of Palamedrix, Inc. on August 31, 2022, enhancing its research capabilities and expanding its service portfolio[173] - The company plans to reduce the cost of performing the SomaScan® assay by transitioning to a less expensive array or Next Generation Sequencing system[179] - The company expects to expand its proteomic content by increasing the number of protein reagents for commercial availability[179] - The company anticipates increased selling, general, and administrative expenses as it introduces new services, broadens its customer base, and grows its business[187]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Exact name of registrant as specified in its charter) SOMALOGIC, INC. Delaware 85-4298912 (State or other jurisdiction of incorporation or organization) 2945 Wilderness Place (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40090 SOMALOGIC, INC. (Exact name of registrant as specified in its charter) Delaware 85-4298912 (State or other jurisdiction of inc ...

Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-K ___________________________________ (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-39796 SOMALOGIC, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-39796 SOMALOGIC, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...

Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-K ___________________________________ (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-39796 SOMALOGIC, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40090 CM LIFE SCIENCES II INC. (Exact name of registrant as specified in its charter) | Delaware | 85-4298912 | | --- | --- | | (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40090 CM LIFE SCIENCES II INC. (Exact name of registrant as specified in its charter) | Delaware | 85-4298912 | | --- | --- | | (State ...